Drug developer Generate Biomedicines raises $400 million in US IPO
Generate BiomedicinesGenerate Biomedicines(US:GENB) Reuters·2026-02-27 01:11

Company Overview - Generate Biomedicines has successfully raised $400 million through its U.S. initial public offering (IPO) by pricing shares at $16 each [1]. Financial Highlights - The IPO raised a total of $400 million, indicating strong investor interest in the company's drug development capabilities [1].